drugset / Trial / NCT03768609

A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults

NCT03768609

Phase 1 Completed 18 enrolled Janssen-Cilag International NV
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to evaluate the effect of a single oral dose of cyclosporine on the pharmacokinetics of a single oral dose of pimodivir when coadministered to healthy adult participants under fasted conditions.

Timeline

Start
2018-12-06
Primary completion
2019-03-06
Completion
2019-03-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide 400 mg
Subject Pimodivir Small molecule 600 mg Oral

Indications

No indication recorded.